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The latent structure of schizotypy and psychosis-spectrum 
symptoms remains poorly understood. Furthermore, molec-
ular genetic substrates are poorly defined, largely due to 
the substantial resources required to collect rich phenotypic 
data across diverse populations. Sample sizes of pheno-
typic studies are often insufficient for advanced structural 
equation modeling approaches. In the last 50 years, efforts 
in both psychiatry and psychological science have moved 
toward (1) a dimensional model of psychopathology (eg, 
the current Hierarchical Taxonomy of Psychopathology 
[HiTOP] initiative), (2) an integration of methods and 
measures across traits and units of analysis (eg, the RDoC 
initiative), and (3) powerful, impactful study designs 
maximizing sample size to detect subtle genomic varia-
tion relating to complex traits (the Psychiatric Genomics 
Consortium [PGC]). These movements are important to 
the future study of the psychosis spectrum, and to resolving 
heterogeneity with respect to instrument and population. 
The International Consortium of Schizotypy Research is 
composed of over 40 laboratories in 12 countries, and to 
date, members have compiled a body of schizotypy- and 
psychosis-related phenotype data from more than 30 000 
individuals. It has become apparent that compiling data 
into a protected, relational database and crowdsourcing 
analytic and data science expertise will result in significant 
enhancement of current research on the structure and bio-
logical substrates of the psychosis spectrum. The authors 
present a data-sharing infrastructure similar to that of the 
PGC, and a resource-sharing infrastructure similar to that 
of HiTOP. This report details the rationale and benefits of 
the phenotypic data collective and presents an open invita-
tion for participation.
Keywords:  data sharing/schizotypy/schizotypal/psychos
is/schizophrenia/phenotype/genetic/ICSR/HiTOP
Recent progress in psychiatric and psychological sci-
ence underscores the need for consolidation and meta-
analysis of phenotypic and molecular data, to model the 
latent structure of the psychosis spectrum. Support for 
this undertaking stems from the inadequacy of categori-
cal diagnoses alone to reflect the apparent spectrum of 
psychotic disorders, quickly developing dimensional con-
ceptualizations of psychopathology,1 the high polygenic-
ity of psychosis symptom dimensions2 (also T. B. Bigdeli 
et  al, unpublished data), and the selective role of rare 
variants in conferring risk for psychosis.3–5
Three initiatives, proceeding largely independently, have 
brought the field toward a critical juncture in which con-
solidation efforts are likely to significantly improve our 
understanding of severe psychopathology: the Psychiatric 
Genomics Consortium (PGC) has enhanced our 
genetic understanding of the psychosis spectrum,6–29 the 
Hierarchical Taxonomy of Psychopathology consortium 
(HiTOP) has endeavored to map the latent structure of 
psychosis,1,30 and the National Institute of Mental Health 
(NIMH) Research Domain Criteria (RDoC) initiative 
has endeavored to develop crosswalks between multiple 
units of analyses (eg, behavioral paradigms relevant to 
schizotypy measures).31–38 Consolidation efforts are also 
consistent with the translational aims of the Roadmap for 
Mental Health Research in Europe (ROAMER) project.39
As van Os et  al40 have recently asserted, the psy-
chosis spectrum requires careful reconstruction. The 
International Consortium for Schizotypy Research 
(ICSR) convened in March of 2017 to discuss current 
research and ways to improve understanding of dimen-
sionality and discontinuity in schizotypy and risk for 
psychosis. The steering committee moved to collectively 
amass data and secured collaborations with the PGC and 
HiTOP to ensure informed data consolidation, reflecting 
strategies implemented by the PGC.41 This report details 
further the rationale for data sharing, the advantages it 
provides to collaborators, and the process by which we 
hope to achieve PGC-, HiTOP-, and RDoC-related aims. 
Broadly, the current goal of the ICSR is to create a data 
resource that will continue to grow and lead to discover-
ies which inform biology and nosology, improve assess-
ment, and identify treatment targets.
Rationale for ICSR Data Sharing
There are several important reasons to amass phenotypic 
data on the psychosis spectrum. There is some consensus 
that the current concept of “schizophrenia,” described by 
diagnostic guidelines and later reified, confines research 
to a constantly changing “construct that does not 
exist.”42 Research on schizotypy, ie, the latent diathesis 
for psychosis and psychosis-spectrum disorders,43 and 
schizotypal signs and symptoms has addressed some of 
the problems of “reification” by characterizing cognitive 
and emotional facets of these symptoms across popula-
tions,44–55 and by comparing categorical high-risk states 
with symptoms in nonclinical, healthy populations. But 
because categorical conceptualizations of high-risk states 
and psychometrically-identified schizotypy can be simi-
larly “reified,” symptom dimensions should be empirically 
evidenced and mapped more comprehensively across a 
broad network of phenotypes, with careful consideration 
of the differences between phenomena and symptoms as 
well as assessments. Due to the heterogeneous nature of 
assessments, limited sampling and insufficient statistical 
power to conduct appropriate structural equation model-
ing, this issue must be addressed with mass collaboration.
Individuals Identified by Current Psychometric 
Approaches Appear to Represent a Small Fraction of a 
Heterogeneous Spectrum Phenotype
Psychometrically identified high-risk groups, based on arbi-
trary cut-offs, have restricted research to the narrow view 
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of psychotic experiences and/or extreme anhedonia (eg, 
“ultra-high risk”), despite evidence from genomic research 
that such individuals are a small sample of the psychosis 
spectrum. Subthreshold psychosis spectrum symptoms 
should be redefined and supplemented to improve predic-
tion of actual onset of psychosis in the general population.
The structure of psychosis and related sequelae, within 
a hierarchical model such as HiTOP, remains relatively 
undefined compared with other dimensional components 
of personality and internalizing/externalizing disor-
ders.1,56 Addressing this concern requires enhanced quan-
titative approaches to refining what we consider to be 
schizotypal traits, ideally involving network, longitudinal 
growth curve, and machine learning approaches—all of 
which are impossible with the currently limited avail-
ability of psychosis-spectrum phenotypic data. This also 
requires careful attention to the constructs involved and 
their conceptualization.57–60
Psychiatric Traits and Symptoms Are Genetically 
Complex, and Light Phenotyping Is Inherent to Large 
Genomic Efforts
Using very large samples collected for genomic mega-
analysis, we experience the drawbacks of necessarily 
lighter phenotyping—dramatically abbreviated scales, or 
even the use of a single item—and a reduced diversity of 
clinical and behavioral data. It has become apparent that 
very small numbers of items are needed to economically 
test genomic relationships in large epidemiological stud-
ies, and the PGC working groups are interested in careful 
psychometric validation of such items. With many differ-
ent datasets, measures, methods, and populations com-
piled for side-by-side comparison, the field is better able 
to identify effective items using methods such as confir-
matory factor analysis (CFA) and item response theory 
(IRT). Moreover, items may be tailored to culture or 
clinical population (case, pedigree, college student). One 
deliverable advance stemming from this effort is develop-
mental and testing support from involved researchers for 
a web application that may be used in large-scale epide-
miological studies. Not only will replicable findings on 
the validity and utility of items be useful to the PGC, but 
these efforts will in turn inform phenotypic measurement.
Schizotypy may Easily Vary by Genomic Profile, and 
Rare Genomic Features Could Isolate Key Symptom 
Dimensions
Genetic subtyping of psychosis-spectrum disorders is 
highly desirable if  it can lead to more accurate classifi-
cation, early prediction, and effective pharmacological 
interventions.61 We observe in genomic psychosis-spec-
trum research that (1) traits are highly polygenic, and yet 
(2) specific rare variants result in psychosis despite low 
genome-wide polygenic risk for schizophrenia.5
Genetic subtyping of complex psychiatric traits has 
been slow to develop, but is moving forward in autism 
spectrum disorder research, where many probands in 
dense pedigrees inherit rare variants which dispropor-
tionally affect cognitive ability.62 It is possible that pro-
bands with rare mutations will have symptoms similar to 
those with more typical genetic profiles, but this is not 
a certainty, and the degree to which probands are atypi-
cal is facilitated by modeling the genetic and phenotypic 
heterogeneity of individuals with autism spectrum dis-
orders.63 The same can be said for schizophrenia. The 
genome is increasingly examined as a dimensional mea-
sure (rather than inspected for genome-wide significant 
hits) to characterize schizophrenia risk, and this is leading 
to findings relevant to classification.25,64–66 These methods, 
although advancing, remain hindered by over-reliance on 
categorical diagnosis. We can facilitate informed deci-
sions about clinically meaningful differences within the 
psychosis spectrum after proper symptom data consoli-
dation efforts across multiple research groups, integrating 
family history, personality, and developmental data.
Dimensional Data Are Statistically Powerful, and 
Some Categorical Measures can Harmonize With 
Dimensional Measures
It is now established that schizotypal symptom expression, 
as currently measured, is detectable across the general pop-
ulation, in biological relatives, and in probands, and can 
be better characterized using a quantitative dimensional 
approach than a dichotomous distinction made with arbi-
trary cut points.58,67 To date, the “ultra-high risk” character-
ization has had moderate clinical utility, and “schizotypy” 
categorical distinctions have been useful insofar as mea-
sures have leveraged several phenotypes at once to gather 
additional evidence of dimensionality across healthy and 
clinical populations.68–81 Again, assumptions that the 
endophenotype is any less complex or heterogeneous than 
schizophrenia itself should be avoided,82 and can lead to 
premature attempts at parsing symptom factors. Reviews 
of the literature that integrate studies using dimensional 
measures have proven to be a promising start,58,83–87 but 
with harmonization of measures across large numbers of 
samples, and proper assessment of measurement invari-
ance, we can begin to build statistically powerful models of 
causation and genome/environment interactions.
In psychiatry, the movement toward a dimensional 
framework for defining and diagnosing psychiatric illness 
is well established and appears to be a more reliable and 
comprehensive model than the Diagnostic and Statistical 
Manual of Mental Disorders-5 (DSM-5) and International 
Classification of Diseases, 10th Revision (ICD-10) cat-
egorical framework.1,88 However, psychosis-spectrum 
conditions prove problematic in the typical internalizing/
externalizing dimensional framework, leading researchers 
to propose and test a distinct psychosis dimension.30,89,90
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There is a need for clarity regarding how this psychosis 
dimension ought to be structured. One camp suggests a 
return to the model which preceded Kraepelin’s classifica-
tion of 2 types of psychosis.91 This would create a single, 
unifying dimension of psychosis which encompasses both 
of Kraepelin’s distinctions,92 and indeed there is ample 
evidence to suggest that the conditions of psychosis share 
common genetic and environmental factors.93 However, a 
singular psychosis dimension may also fail to capture the 
complexity of a given condition. Multiple studies have 
found that a 5-dimensional structure, including dimen-
sions labeled internalizing, disinhibited externalizing, 
antagonistic externalizing, detachment, and thought dis-
order, better harmonizes with existing categorical diag-
noses.94–96 Yet other researchers have sought to blend the 
parsimony of a single dimension with the nuance of a 
5-dimensional structure using a bi-factor model in which 
a general psychosis dimension is assessed first, and then 
used as a guide for assessment by the 5 specific symptom 
dimensions.97,98 The efforts of ICSR will further inform 
these findings and evaluate current proposed models.
The Clinic: Current High-Risk Classification 
Approaches Are Not Sufficient to Understand Risk
Field evidence has yet to justify a DSM risk syndrome 
category, with only 11% meeting criteria for ultra-high 
risk (UHR) classification developing psychosis in one 
study,99 and 39% in another.100 Inclusion of an attenu-
ated psychosis syndrome into the full text of DSM-5.1 is 
still being debated.101 The best psychometrically guided 
predictors in nonclinical populations, outside of fam-
ily history, are extreme scores on symptom surveys, and 
even they do not predict actual psychosis at high rates. 
Negative schizotypy studies find an impressive 24% of 
students with (categorical) extreme social anhedonia 
develop schizophrenia-spectrum psychopathology, but 
not typically psychosis. In general, schizotypy measures 
in predicting psychosis have been underwhelming (for 
review of this literature, see Docherty and Sponheim85). 
Family and molecular genetic studies have provided evi-
dence that dimensionally measured negative symptoms 
may hold predictive utility55,68,80,102–105 but again, phe-
notyping in genomic studies thus far has been light, or 
samples too small, to adequately examine the genomic 
architecture of psychosis-related symptom dimensions.
The take-home message of this research is (1) family 
history predicts general psychopathology, (2) subthresh-
old symptoms of a psychosis-spectrum disorder predict 
symptoms of the disorder, (3) there is little diagnostic 
specificity with regard to prediction, and (4) the more 
prevalent the disorder, the greater role environment plays 
in etiology. Given these points, perpetuating the litera-
ture on clinically measured high risk without refining 
the phenotype is unlikely to improve research on early 
intervention.
One function of the ICSR can be to better operational-
ize phenotypes in accordance with dimensional models, 
and to improve understanding of the relation of schizo-
typy to other psychosis spectrum phenomenology, eg, 
of UHR and frank psychosis. Language, social behav-
ior, emotional expression, beliefs, perceptual experience, 
and emotional response can all be reduced to behavioral 
function, and these can be normed using large interna-
tional samples. Relatedly, an advantage of the effort is to 
explore the role of culture on illness expression and phe-
notype. The ICSR is well poised to accomplish this, given 
that it is truly international and intercultural.
The NIMH, PGC, HiTOP, and ICSR are mov-
ing toward a framework that is more compatible with 
dimensional biological risk, and the UHR/familial-high 
risk (FHR) research community is encouraged to col-
laborate with these efforts to improve clinical outcomes. 
Importantly, the addition of dimensional measures is 
meant to enhance our understanding of the latent struc-
ture of psychosis and psychosis risk, but not mire us in 
assumptions about diagnosis or dimension.
An Open Invitation
Three primary steps of this initiative are illustrated 
in figure  1. Data distributions are examined and large 
matrices of data used to develop empirically driven 
covariance structures. Models will implicate facets of 
schizotypy and psychosis-related symptoms relevant to 
specific intervention targets, and will be assessed rela-
tive to genomic findings. These data will include both 
clinical and psychometric measures. With larger sample 
sizes, structural equation modeling, item response theory, 
machine  learning, and other relevant methods may be 
implemented to validate models of latent structure.
The ICSR requires a massive, collective effort to 
obtain and maintain data to facilitate efficient analysis 
and replication. This initiative is facilitated in part by 
Anna Docherty’s cluster farm and by the Utah Center 
for Genomic Discovery (UCGD), a University of Utah 
initiative to integrate patient genome information into 
health care and develop tools for genome interpreta-
tion. Together this accounts for 2.5 PB of disc storage. 
There is a core team of 6 on-site data scientists and ana-
lysts, including authors Anna Docherty, John Anderson, 
Andrey Shabalin, and Daniel Adkins. Computing space, 
resources for proband and extended pedigree data col-
lection, and an active undergraduate data collection are 
available to collaborative PIs. The authors of this publi-
cation themselves share broad skill sets and actively seek 
collaboration with other interested PIs.
“Schizotypy” is a complex, multidimensional con-
struct, whose dimensions differ widely both in the degree 
and specificity with which they reflect genetic liability 
to schizophrenia.67 Thus to date, our consolidated data 
come from multiple community, risk, family, and case 
Downloaded from https://academic.oup.com/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby059/4996806
by University of Utah Eccles Health Sciences Library user
on 21 May 2018
Page 5 of 8
Psychosis-Spectrum Data Sharing Initiative
populations. Thirty of our collaborators share clinical 
and/or cognitive data from first-degree biological rela-
tives, 19 share college student data, and 21 share com-
munity data. Most have also collected data in cases, with 
measures that can be harmonized and meta-analyzed. 
The ICSR has amassed approximately 40 000 samples 
with clinical phenotype data including items from schizo-
typy and schizotypal personality assessments. We hope 
to double samples over the following year and plan to 
apply for additional external funding. These data and 
measures will be characterized in a first publication with 
all collaborators.
A portal for participation is housed on the ICSR 
website, at srconsortium.org. PIs or institutions may 
use this website to contact the data sharing facilitators. 
Participation includes invitation to collaborate on anal-
yses and publication of scientific findings. Projects will 
be managed in the same way data analytics are handled 
within PGC, such that individuals and research teams 
submit proposals to analyze data. One example analysis 
by the ICSR and PGC may be focused on item refinement 
for future genomic research using Smartphone applica-
tions. Another study will pilot items in a genetic study of 
undergraduate samples.
We draw attention to the precedent of the PGC to 
effectively organize and collaborate on a large scale. This 
is done with adherence to common principles described 
in the inaugural publication.41 Participating members 
will use identical guidelines and are in active consulta-
tion with the PGC Director Patrick Sullivan to promote 
external review of the collaborative.
With the introduction of spectrum phenotypes in 
DSM-5, the field is better positioned to synthesize 
research to refine signs and symptoms. Impactful psycho-
sis research in the present day reflects collective efforts to 
understand (1) the genetic architecture of psychosis, and 
(2) the latent structure of the psychosis spectrum. These 
efforts can be symbiotic and benefit both genomic and 
phenotypic research.
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